Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial

Hepatology

A randomised placebo controlled trial of VSL#3^® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease

BMC Gastroenterol

Chong PL, Laight D, Aspinall RJ, Higginson A, Cummings MH

doi: 10.1186/s12876-021-01660-5

Hepatology

Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease

Gastroenterology.

Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, Childs CE, Del Fabbro S, Beavis J, Moyses HE, Clough GF, Sethi JK, Patel J, Wright M, Breen DJ, Peebles C, Darekar A, Aspinall R, Fowell AJ, Dowman JK, Nobili V, Targher G, Delzenne NM, Bindels LB, Calder PC, Byrne CD

doi: 10.1053/j.gastro.2020.01.031.

Hepatology

Patient-reported Outcomes (PROs) in Patients with Non-alcoholic Fatty Liver Disease: A Narrative Review of CLDQ-NAFLD/NASH

J Gastroenterol Hepatol.

Yamamura S, Nakano D, Hashida R, Tsutsumi T, Kawaguchi T, Okada M, Isoda H, Takahashi H, Matsuse H, Eguchi Y, Sumida Y, Nakajima A, Gerber L, Younossi ZM, Torimura T

doi: 10.1111/jgh.15172.

Hepatology

Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis

Lancet Gastroenterol Hepatol.

Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, Yang H, Liu C, Kam LY, Tan XXE, Chien N, Trinh S, Henry L, Stave CD, Hosaka T, Cheung RC, Nguyen MH

doi: 10.1016/S2468-1253(20)30077-7.

Hepatology

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study

J Hepatol.

Harrison SA, Alkhouri N, Davison BA, Sanyal A, Edwards C, Colca JR, Lee BH, Loomba R, Cusi K, Kolterman O, Cotter G, Dittrich HC

doi: 10.1016/j.jhep.2019.10.023.

ColonoscopyInflammatory Bowel Disease

Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial

Clin Gastroenterol Hepatol.

Bommelaer G, Laharie D, Nancey S, Hebuterne X, Roblin X, Nachury M, Peyrin-Biroulet L, Fumery M, Richard D, Pereira B, Goutte M, Buisson A, POPCUR study group

doi: 10.1016/j.cgh.2019.08.041.

Hepatology

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Lancet.

Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ, REGENERATE Study Investigators.

doi: 10.1016/S0140-6736(19)33041-7.

Gastroesophageal Reflux Disease (GERD)

Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease

Eur J Gastroenterol Hepatol.

Wilkinson J, Wade A, Thomas SJ, Jenner B, Hodgkinson V, Coyle C

doi: 10.1097/MEG.

Hepatology

Saroglitazar, a PPAR-α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double-Blind Phase 2 Trial

Hepatology

Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N

doi: 10.1002/hep.31843

Related content

A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease

Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease

Patient-reported Outcomes (PROs) in Patients with Non-alcoholic Fatty Liver Disease: A Narrative Review of CLDQ-NAFLD/NASH

Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study

Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease

Saroglitazar, a PPAR-α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double-Blind Phase 2 Trial

A randomised placebo controlled trial of VSL#3^® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease